Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 29 July 2025, 23:39 HKT/SGT
Share:
    

Source: Biolog, Inc
Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence
Biolog, a leading provider of microbial identification and phenotypic characterization tools and services, announced today that both its anaerobic media and anaerobic chambers have received CE marking, clearing the way for broader international use

HAYWARD, CALIFORNIA, July 29, 2025 - (ACN Newswire) - Biolog, a leading provider of microbial identification and phenotypic characterization tools and services, announced today that both its anaerobic media and anaerobic chambers have received CE marking, clearing the way for broader international use. The media and chambers were part of Biolog's acquisition of Anaerobe Systems earlier this year with the objective of bringing class-leading tools for microbiology to the rapidly growing clinical, microbiome, and agricultural markets.

Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture ExcellenceToday, Biolog's TruPRAS™ media is the only commercial media manufactured under true pre-reduced, anaerobically sterilized conditions, preventing the formation of harmful byproducts that can be toxic to anaerobic organisms. This line of media products, which has been approved for In Vitro Diagnostic (IVD) use by the USA FDA for years, has now also achieved CE marking under the requirements of the EU IVDR regulation 2017/746. With zero recalls or field actions throughout their extensive history, these products enable transport of specimens and growth of fastidious anaerobes that play important roles in disease pathology - supporting clinical diagnostics in medical laboratories.

"The IVDR/CE mark is a major milestone that recognizes the high standard of our anaerobic media and its value in supporting critical diagnostic workflows," said Robert Wicke, CEO at Biolog. "We're proud that clinical labs throughout Europe can now benefit from the same reliable performance that researchers and clinicians in the U.S. have trusted for decades."

Biolog's anaerobic chambers have also received the CE mark, affirming their safety and performance for use in any research settings throughout the world. With unique InstaSleeve™ technology, these ergonomic, gloveless chambers offer superior processing dexterity while working in a fully anaerobic environment and are a preferred tool for microbiologists in both clinical and academic settings. In addition, Biolog is releasing an upgrade to enable hypoxic or microaerophilic conditions in the same chamber, for organisms that require specific, low concentrations of oxygen to thrive.

"This dual achievement reinforces Biolog's commitment to advancing global access to high-quality tools for anaerobic microbiology," said Wicke. "Whether you're working with challenging clinical isolates or conducting fundamental research, Biolog now provides dependable CE-marked solutions that meet your needs."

About Biolog

Biolog offers tools, services, and support for comprehensive cellular characterization and multi-omic identification of bacteria, yeast, and fungi. Our products also enable phenotypic profiling of microbial and mammalian cells for a range of applications, including supporting the culture of fastidious anaerobes with our line of gloveless chambers and pre-reduced media. Learn more at biolog.com

Contact Information
John Proctor, Ph.D.
CCO
jproctor@biolog.com
(408)306-0414.

SOURCE: Biolog, Inc.




Topic: Press release summary
Source: Biolog, Inc

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Naoris Protocol Announces Upcoming TGE for $NAORIS  
July 29, 2025 23:59 HKT/SGT
Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence  
July 29, 2025 23:39 HKT/SGT
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases  
July 29, 2025 23:13 HKT/SGT
GTJAI Achieved 'Carbon Neutrality' at Operational Level for the Third Consecutive Year  
July 29, 2025 23:06 HKT/SGT
Mitsubishi Heavy Industries Concludes Agreement with Modius to Provide DCIM Solutions for Data Centers Worldwide  
Tuesday, July 29, 2025 7:00:00 PM
Wintermar Offshore (WINS:JK) Reports 1H2025 Results  
July 29, 2025 18:56 HKT/SGT
Set at the Osaka-Kansai Expo venue! Detailed program announced for the "OSAKA JAPAN SDGs Forum"  
Tuesday, July 29, 2025 1:30:00 PM
Unitree Races Toward IPO as Robot Applications Accelerate: Shoucheng Holdings Unlocks Dual-Engine Gains  
July 29, 2025 11:30 HKT/SGT
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma  
Tuesday, July 29, 2025 8:01:00 AM
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China  
July 29, 2025 04:00 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: